Literature DB >> 8006883

Synergism of interleukin 1 and interleukin 6 induces serum amyloid A production while depressing fibrinogen: a quantitative analysis.

H Rokita1, L D Loose, L M Bartle, J D Sipe.   

Abstract

OBJECTIVE: Production of the serum amyloid A (SAA) proteins in the liver of patients with arthritis can be increased from approximately 1 microgram/ml to > 1000 micrograms/ml, while fibrinogen (Fg) can be increased from 2 to 9 mg/ml. The increases appear to be regulated by mediators similar to those found in inflamed joints, e.g., interleukins 1 and 6 (IL-1 and IL-6, respectively). The sensitivity and dose response of SAA and Fg synthesis by hepatoma cells to IL-1 and IL-6 was investigated to understand the relationship between the inflammatory cytokines produced in inflamed joints and the acute phase protein response in the liver of arthritis patients.
METHODS: SAA and Fg mRNA and protein production in human Hep3B cells stimulated by human monocyte conditioned medium (CM) containing known amounts of IL-1 and IL-6, or stimulated by corresponding concentrations of recombinant IL-1 and IL-6 was analyzed by ELISA and Northern blot hybridization techniques.
RESULTS: Increases in SAA mRNA and protein were dose dependent in the presence of IL-1 and IL-6 at concentrations ranging from 0.1 and 1 ng/ml, respectively, to 10 and 100 ng/ml, respectively. In the presence of IL-1 receptor antagonist (IL-1ra), there was a 75% decrease in SAA production and > 100% increase in Fg production by cells stimulated with CM.
CONCLUSION: Our results demonstrate that the thousand fold dynamic range associated with the acute phase SAA response requires IL-1 acting synergistically with cytokine(s) like IL-6. Optimum conditions for apoSAA production are suboptimal for Fg as indicated by the differential effects of IL-1ra.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006883

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Apolipoprotein serum amyloid A down-regulates smooth-muscle cell lipid biosynthesis.

Authors:  B M Schreiber; M Veverbrants; R E Fine; J K Blusztajn; M Salmona; A Patel; J D Sipe
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

2.  Mouse serum amyloid A (SAA) proteins isolated by two-dimensional electrophoresis: characterization of isotypes and the effect of separate and combined administrations of cytokines, dexamethasone and lipopolysaccharide (LPS) on serum levels and isotype distribution.

Authors:  C Foyn Bruun; K Sletten; G Marhaug
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

3.  Serum amyloid A protein enhances the activity of secretory non-pancreatic phospholipase A2.

Authors:  W Pruzanski; F C de Beer; M C de Beer; E Stefanski; P Vadas
Journal:  Biochem J       Date:  1995-07-15       Impact factor: 3.857

4.  Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.

Authors:  Christopher P Sullivan; Stephanie E Seidl; Celeste B Rich; Michel Raymondjean; Barbara M Schreiber
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

5.  IL-1 receptor antagonist (IL-1Ra) does not inhibit the production of C-reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumour cells.

Authors:  C Gabay; B Genin; G Mentha; P B Iynedjian; P Roux-Lombard; P A Guerne
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.